PHusis Therapeutics is a biotechnology company founded in 2009 that specializes in developing precision medicines using its proprietary computational modeling platform, PHuDock. This platform efficiently identifies inhibitors of proteins with regulatory PH-domains that contribute to cancer growth, allowing the company to rapidly and cost-effectively detect drug leads. PHusis has created a pipeline targeting significant cancer markers including PDK1, mutant KRAS, and NRAS.
What makes PHusis stand out is its personalized treatment approach based on the patient's mutational profile. This ensures that only those with relevant targets receive therapy, potentially improving treatment efficacy. With a focus on health and wellness, PHusis is at the forefront of developing advanced solutions for tailored cancer treatment.
Currently, the company has not disclosed its last investment details and investors, but its innovative approach to precision medicine and its potential to revolutionize cancer treatment make it an intriguing prospect for venture capitalists seeking opportunities in the biotechnology sector.
There is no investment information
No recent news or press coverage available for PHusis Therapeutics.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
